February 13th 2024
The analysis of several oral antidiabetic drugs revealed patients taking SGLT2 inhibitors had more NAFLD regression and fewer adverse liver-related outcomes.
February 12th 2024
February 7th 2024
New research from a first-in-human study of a novel procedure involving electroporation of the superficial layer of the mucosa in the small intestine could help eliminate need for insulin in some people with type 2 diabetes.
In this episode, hosts offer their reaction to topline data from the SURMOUNT-2 trial examining tirzepatide for weight management in T2D, the FDA's clearance of the Omnipod GO device, and results of the CLVer trial.
Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our April 2023 month in review features top new studies, FDA approvals, and an overview of news surrounding Abbott readers.
George Bakris, MD, shares best practices for co-management and providing comprehensive care for patients with diabetic kidney disease.
Dr George Bakris reviews the clinical trial data for finerenone and provides insights on treatment selection, including the potential benefits of combination therapy with finerenone and SGLT2 inhibitors, in managing diabetic kidney disease.
Dr George Bakris elaborates on the risk factors, monitoring, treatment objectives, and the impact of diet and exercise in preventing the progression of diabetic kidney disease.
Data from the SURMOUNT-2 trial demonstrate use of tirzepatide 10 mg and 15 mg were associated with mean weight reductions of 13.4% and 15.7%, respectively, with more than 80% of tirzepatide users achieving a body weight reduction of 5% or greater.
Announced on April 25, 2023, the FDA's clearance of the Omnipod GO marks the first-of-its-kind for a basal-only insulin pod and is indicated for use as an insulin delivery device for people with type 2 diabetes aged 18 or older.
An analysis of adults with T2D found a higher intake of sugar-sweetened beverages was associated with higher all-cause mortality and CVD incidence, whereas healthier beverage options were inversely associated with all-cause mortality.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss the implications of increased CGM access through a recent CMS expansion and take a deep dive into the latest Abbott news, including dispelling misconceptions surrounding the recall announcement.
A cross-sectional analysis of data is offering a snapshot of trends in the treatment of 7 common chronic health conditions among incarcerated populations in the US relative to the general population.
A new pilot study assessing the shelf life of insulin when stored at room temperature during the summer in India suggests most insulins maintained 95% potency or greater at 4 months relative to refrigerated insulin.
Announced on April 6, the recall, which is the most serious of its kind, includes all Readers used with the FreeStyle Libre, FreeStyle Libre 14 day, and FreeStyle Libre 2 Flash Glucose Monitoring Systems distributed from November 2017-February 2023, which totals more than 4 million devices in the US.
Data from the PROMISE II study detail the effects of transcatheter arterialization procedures with the LimFlow System for reducing the rate of amputation in people with chronic limb-threatening ischemia.
This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.
In this episode, hosts celebrate the 10-year anniversary of the approval of the first SGLT2 inhibitor, discuss announcements related to insulin pricing, and take a deep dive into 24-week data from the MOMENTUM trial.
Our latest endocrine case report from Brady Pregerson, MD, features a patient in their mid-70s with a history of diabetes mellitus and end-stage kidney disease presenting with 6 days of gradually worsening right ear pain. Can you determine the correct diagnosis?
A retrospective analysis comparing propensity score matched metformin users against sulfonylurea users, results of the study indicate metformin use was associated with a 24% reduction in relative risk of developing osteoarthritis.
A phase 2 trial comparing once weekly basal insulin Fc against once daily insulin degludec, results of the study will help provide the basis for forthcoming phase 3 research examining the agent.